Soticlestat (TAK-935)
Updated: 07/06/2022
Pipeline Type
Phase Of Development
Sponsors and Collaborators
Takeda Pharmaceuticals
Mechanism of Action
Mechanism Description
Cholesterol 24-hydroxylase (CH24H) Inhibitor Soticlestat exerts its potential effects via the inhibition of Cholesterol 24-hydroxylase (CH24H). CH24H converts cholesterol to 24S-hydroxycholesterol (24HC) in the brain. Reduction of 24HC has been shown to reduce glutamatergic signaling and inflammation, which may have downstream effects on seizure susceptibility.
Populations Tested In
Developmental Epileptic Encephalopathies / Dravet syndrome and Lennox-Gastaut syndrome
Other Resources
Special FDA Designation
Nonprofit or Government Support
Nonprofit or Government Support Description
Previous Presentations
EILAT 2018
ASENT 2019
SNMMI 2019
AEDD 2019
EPC 2020
AAN 2020
AES 2020
AAN 2021
AES 2021
BPNA 2022
EILAT 202
Location of Clinical Trials
United States, Australia, Belgium, Canada, China, France, Greece, Hungary, Italy, Japan, Latvia, the Netherlands, Poland, Serbia, Spain, Ukraine*, Russia*
*No current active recruitment in these countries